References
- Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 montreal world congress of gastroenterology. Can J Gastroenterol. 2005;19(SupplA):5A–36. PMID:16151544.
- Burisch J, Pedersen N, Čuković-Čavka S, et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut. 2014;63(4):588–597. PMID:23604131.
- Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA) patient survey. J Crohn’s Colitis. 2007;1:10–20.
- Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 8;353(23):2462–2476.
- Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012 Feb;142(2):257-65.e1-3. Epub 2011 Nov 4. DOI:10.1053/j.gastro.2011.10.032
- Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan;146(1):85–95. quiz e14-5. Epub 2013 Jun 2. DOI:10.1053/j.gastro.2013.05.048
- Lobatón T, Vermeire S, van Assche G, et al. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39(6):579–594.
- Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.
- Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(23):2183–2196.
- Wilson M, Kerrigan M, Smyth M, et al. Cost-effectiveness of vedolizumab compared with conventional therapy for treatment of moderately-to-severely active ulcerative colitis in the United Kingdom. United European Gastroenterol J. 2015 Oct;3(5 Suppl):146–687. DOI:10.1177/2050640615601623.
- Wilson M, Kerrigan M, Smyth M, et al. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab for treatment of moderately-to-severely active ulcerative colitis in the United Kingdom. United European Gastroenterol J. 2015 Oct;3(5 Suppl):146–687. DOI:10.1177/2050640615601623.
- Essat M, Tappenden P, Ren S, et al. Vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis: a single technology appraisal. School of Health and Related Research (ScHARR); Pharmacoeconomics. 2016 Mar;34(3):245-257. doi:10.1007/s40273-015-0334-3.
- Vedolizumab for treating moderately to severely active ulcerative colitis (TA342). London: National Institute of Health and Care Excellence (NICE); 2015.
- Tsai HH, Punekar YS, Morris J, et al. A model of the long-term cost-effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2008;28:1230–1239.
- Vedolizumab 300mg powder for concentrate for solution for infusion (Entyvio®) SMC No. (1045/15). Scottish Medicines Consortium (SMC); 2015.
- Cost-effectiveness of vedolizumab (Entyvio®) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNF-α) antagonist. Ireland: National Centre for Pharmacoeconomics (NCPE); 2015.
- Yokomizo L, Limketkai B, Park KT. Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis. BMJ Open Gastro. 2016;3:e000093. DOI:10.1136/bmjgast-2016-000093.